Score Your Stock

US stock · figures in US dollars · scored on full-year results

Zimmer Biomet Zimmer Biomet Holdings, Inc. Common Stock

ZBH · Healthcare · Medical Devices
Bottom 25% of scored stocks
OkayBottom 25% of scored stocks
Weak Spot

Zimmer Biomet scores 45/100 on fundamentals: in the bottom 25% of 503 scored S&P 500 stocks. Its strongest area is Financial Safety (67/100); its weakest is Price Fairness (17/100). It carries 1 warning flag: Weak Spot.

Best
Financial 67
Weakest
Price 17
  • Carries a Weak Spot flag

An expensively priced stock, but price fairness needs attention.

What looks good
What to watch
Mkt capUS$ 18.0b#423 of 503 in the S&P 500EPSUS$ 4.12P/E22.3×✓ vs sector median 30.5×P/B1.4×✓ vs sector median 4×Div yield1%Bottom 42% in the S&P 50052w range · 63% of range79.12103.70
as of 31 Oct 2026

Nearby peers

Ranks #44 of 60 in Healthcare by score

#1Universal Health Services79#42Johnson & Johnson48#43CVS Health45
#44Zimmer Biomet45
#45Abbott Laboratories44#46Merck &43

One-Minute Summary

Why Zimmer Biomet scores 45

An expensively priced stock, but price fairness needs attention.

What looks good
What to watch

Business Strength

30
Why 30?
Pillar score: (0 + 1 + 0 + 1 + 1) = 3 of 10 points → 30
Return on Equity (ROE)6%Weak4-Year Revenue Growth+5%/yrOkay4-Year Profit Growth-8%/yrWeakNet Profit Margin9%OkayQuarterly Momentum+9%Okay
Show 3 charts

Net Profit & Equity, with ROE

Net Profit ↓ -21.2%Equity → +1.1%ROE % 6.4%
Net ProfitEquityROE %
1.0b904m705m807m12.5b12.5b12.7b12.6b202320242025TTM8.2%7.2%5.6%6.4%

Revenue & Net Profit, with Net Margin

Revenue ↑ +15.1%Net Profit ↓ -21.2%Net Margin % 9.5%
RevenueNet ProfitNet Margin %
7.4b7.7b8.2b8.5b1.0b904m705m807m202320242025TTM13.8%11.8%8.6%9.5%

Sales grew about 15.1% over 4 years: customers keep spending more with this company.

Profit fell about 21.2% from where it was 4 years ago: the boom has cooled off.

Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)

Revenue ↑ +19.3%Net Profit ↓ -20.4%Net Margin % 9.1%
RevenueNet ProfitNet Margin %
1.8b2.0b1.9b2.1b2.0b2.2b2.1b2.2b249m240m182m153m231m139m238m198mQ3'24Q4'24Q1'25Q2'25Q3'25Q4'25Q1'26Q2'2613.7%11.8%9.5%7.4%11.5%6.2%11.4%9.1%
▲▼▲▼▼▼▲▲

Sales grew about 19.3% over the last 8 quarters: customers keep spending more with this company.

Profit fell about 20.4% over the last 8 quarters.

Why 67?
Pillar score: (1 + 2 + 1) = 4 of 6 points → 67
Debt-to-Equity0.6×OkayCurrent Ratio1.7×StrongInterest Coverage4.2×Okay
Show 2 charts

Debt vs Equity, with D/E ratio

Total Debt ↑ +29.7%Equity → +1.1%D/E 0.6×
Total DebtEquityD/E
5.8b6.2b7.5b7.5b12.5b12.5b12.7b12.6b202320242025TTM0.5×0.5×0.6×0.6×

Borrowings grew about 29.7% over 4 years: watch this; rising debt adds pressure in bad times.

Short-term assets vs bills, with Current Ratio

Current Assets ↑ +10.6%Current Liabilities ↑ +5.5%Current Ratio 1.7×
Current AssetsCurrent LiabilitiesCurrent Ratio
4.6b4.7b5.1b5.1b2.9b2.5b2.6b3.0b202320242025TTM1.6×1.9×2×1.7×
Why 50?
Pillar score: (0 + 2 + 2 + 0) = 4 of 8 points → 50
Dividend Quality1%Weak
Payout ratio: 23%
Operating Cash FlowPositive & growingStrongFree Cash FlowPositive & growingStrongCash & Cash EquivalentsShrinking & thinWeak
Show 3 charts

Operating vs Free Cash Flow

Operating CF ↑ +10.2%Free CF ↑ +18.1%
Operating CFFree CF
1.6b1.5b1.7b1.7b1.2b1.1b1.4b1.4b202320242025TTM

The business generates real cash, and more of it each year: a very healthy sign.

Cash vs Total Debt

Cash → -1.4%Short-Term Debt ↑ +33.5%Total Debt ↑ +29.7%
CashShort-Term DebtTotal Debt
416m526m592m410m900m863m587m1.2b5.8b6.2b7.5b7.5b202320242025TTM

Dividends per Share, with Yield

DPS (cents) → +0%Yield % 1%
DPS (cents)Yield %
242424242424242424249696969620222023202420250.9%0.8%0.9%1%

Dividends per share have been maintained or raised: management shares the rewards with you.

Why 17?
Pillar score: (0 + 1 + 0) = 1 of 6 points → 17
P/E Ratio22.3×WeakP/B Ratio1.4×OkayPEG Ration/m (growth not measurable)Weak
Show chart

Share Price: Weekly Closes (not part of the score)

US$ 100.72US$ 91.31US$ 81.90Oct '25Feb '26Jun '26Oct '26

The share price is down about 5% over the past year.

Why 58?
Pillar score: (1 + 0 + 2 + 2 + 1 + 1) = 7 of 12 points → 58
Earnings ConsistencyUnevenOkayDebt Trend (4yr)RisingWeakShare Count Trend (4yr)-2%/yrStrongInventory vs Sales (4yr)-6.4 pp/yr vs salesStrongAsset Turnover Trend (4yr)+8.5%OkayQuarterly Consistency2 of 4 quarters downOkay
Show chart

Revenue vs Inventory, with Inventory % of Revenue

Revenue ↑ +15.1%Inventory ↓ -4.8%Inv. % of Rev. 26.7%
RevenueInventoryInv. % of Rev.
7.4b7.7b8.2b8.5b2.4b2.2b2.3b2.3b202320242025TTM32.3%29.1%27.8%26.7%
Ranks #44 of 60 in Healthcare by score

Sector peers

#1Universal Health Services79#42Johnson & Johnson48#43CVS Health45
#44Zimmer Biomet (you)45
#45Abbott Laboratories44#46Merck &43

Full Financial History

Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.

Financial YearRevenueNet ProfitOperating Cash FlowFree Cash FlowCapExCashTotal DebtShort-Term DebtEquityCurrent AssetsCurrent LiabilitiesTotal AssetsTotal LiabilitiesInventoryDividendsReturn on Equity (ROE)Net Profit MarginDebt-to-EquityCurrent RatioInterest CoverageDividend Payout RatioDiv yieldP/E RatioP/B RatioPEG Ratio
2026US$ 8.5bUS$ 806.7mUS$ 1.7bUS$ 1.4bUS$ -341.5mUS$ 410.0mUS$ 7.5bUS$ 1.2bUS$ 12.6bUS$ 5.1bUS$ 3.0bUS$ 22.8bUS$ 10.2bUS$ 2.3b-6%9%0.6×1.7×4.2×23%----
2025US$ 8.2bUS$ 705.1mUS$ 1.7bUS$ 1.4bUS$ -276.9mUS$ 591.9mUS$ 7.5bUS$ 587.1mUS$ 12.7bUS$ 5.1bUS$ 2.6bUS$ 23.1bUS$ 10.4bUS$ 2.3bUS$ 96.0m6%9%0.6×2.0×3.8×27%1%24.8×1.4×0.6
2024US$ 7.7bUS$ 903.8mUS$ 1.5bUS$ 1.1bUS$ -356.8mUS$ 525.5mUS$ 6.2bUS$ 863.0mUS$ 12.5bUS$ 4.7bUS$ 2.5bUS$ 21.4bUS$ 8.9bUS$ 2.2bUS$ 96.0m7%12%0.5×1.9×5.8×22%1%22.6×1.6×0.7
2023US$ 7.4bUS$ 1.0bUS$ 1.6bUS$ 1.2bUS$ -394.5mUS$ 415.8mUS$ 5.8bUS$ 900.0mUS$ 12.5bUS$ 4.6bUS$ 2.9bUS$ 21.5bUS$ 9.0bUS$ 2.4bUS$ 96.0m8%14%0.5×1.6×6.3×20%1%23.8×2.0×-